Tilray Brands reported significant losses in its third-quarter results, with sales declining slightly and net loss widening considerably compared to the previous year. The company also received a Nasdaq compliance notice regarding its share price, which must stay above $1 to maintain its listing. These events may have contributed to the 18% decline in its stock price over the last week, countering the broader market's 5% rise. Despite revised revenue guidance suggesting potential future improvements, the immediate financial challenges seemed to weigh more heavily on investor sentiment during this period.

We've identified 2 risks for Tilray Brands that you should be aware of.NasdaqGS:TLRY Earnings Per Share Growth as at Apr 2025

AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Over the past year, Tilray Brands' (NasdaqGS:TLRY) total shareholder return has decreased by 73.22%, significantly underperforming the broader US market, which saw a 3.6% rise, and the US Pharmaceuticals industry, which fell by 8.6%. This decline reflects the underlying challenges highlighted in their recent earnings report, including a substantial widening of net losses and a slight dip in sales. The company's revenue forecast of US$850 million to US$950 million for FY 2025 suggests a cautious optimism, yet the widening net losses remain a considerable concern.

The share price adjustment also responds to Tilray receiving a Nasdaq compliance notice due to its current trading price below the US$1 minimum bid requirement, with a deadline of September 21, 2025, for compliance. With the stock trading at 61.5% below the consensus analyst fair value estimate, and a target price significantly higher than the present share price, there remains distinct market skepticism regarding near-term prospects. Despite these challenges, the company's strategic initiatives, like product innovations and expanded distribution, may potentially improve future performance metrics if successfully executed.

Our valuation report here indicates Tilray Brands may be undervalued.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Story Continues

Companies discussed in this article include NasdaqGS:TLRY.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments